New combo therapy aims to fight tough esophageal cancer
Disease control
Recruiting now
This study tests a shorter course of chemotherapy and radiation combined with the immunotherapy drug camrelizumab for people with advanced esophageal cancer that cannot be removed by surgery. About 98 participants will receive either the combination followed by maintenance immuno…
Phase: PHASE2 • Sponsor: Ning Jiang, M.D./Ph.D. • Aim: Disease control
Last updated May 13, 2026 16:02 UTC